These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 11693902)
21. The interaction of radiation therapy and antiangiogenic therapy. O'Reilly MS Cancer J; 2008; 14(4):207-13. PubMed ID: 18677126 [TBL] [Abstract][Full Text] [Related]
22. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Klement G; Huang P; Mayer B; Green SK; Man S; Bohlen P; Hicklin D; Kerbel RS Clin Cancer Res; 2002 Jan; 8(1):221-32. PubMed ID: 11801563 [TBL] [Abstract][Full Text] [Related]
23. Antiangiogenic therapies in breast cancer. Sarmiento R; D'Andrea MR; Cacciamani F; Salerno F; Gasparini G Curr Opin Investig Drugs; 2009 Dec; 10(12):1334-45. PubMed ID: 19943205 [TBL] [Abstract][Full Text] [Related]
24. Antiangiogenic cancer therapy. Cao Y Semin Cancer Biol; 2004 Apr; 14(2):139-45. PubMed ID: 15018898 [TBL] [Abstract][Full Text] [Related]
25. Antiangiogenic effect of metronomic paclitaxel treatment in prostate cancer and non-tumor tissue in the same animals: a quantitative study. Lennernäs B; Albertsson P; Damber JE; Norrby K APMIS; 2004 Mar; 112(3):201-9. PubMed ID: 15153162 [TBL] [Abstract][Full Text] [Related]
26. Antiangiogenic properties of metronomic chemotherapy in breast cancer. Tonini G; Schiavon G; Silletta M; Vincenzi B; Santini D Future Oncol; 2007 Apr; 3(2):183-90. PubMed ID: 17381418 [TBL] [Abstract][Full Text] [Related]
28. Metronomic scheduling: the future of chemotherapy? Gasparini G Lancet Oncol; 2001 Dec; 2(12):733-40. PubMed ID: 11902515 [TBL] [Abstract][Full Text] [Related]
29. Antiangiogenic cancer therapy: why do mouse and human patients respond in a different way to the same drug? Cao Y Int J Dev Biol; 2011; 55(4-5):557-62. PubMed ID: 21858776 [TBL] [Abstract][Full Text] [Related]
30. Tumour eradication by antiangiogenic therapy: analysis and extensions of the model by Hahnfeldt et al. (1999). d'Onofrio A; Gandolfi A Math Biosci; 2004 Oct; 191(2):159-84. PubMed ID: 15363652 [TBL] [Abstract][Full Text] [Related]
31. Current development status of small-molecule vascular disrupting agents. Chaplin DJ; Horsman MR; Siemann DW Curr Opin Investig Drugs; 2006 Jun; 7(6):522-8. PubMed ID: 16784022 [TBL] [Abstract][Full Text] [Related]
33. Angiogenesis inhibition in solid tumors. Rosen LS Cancer J; 2001; 7 Suppl 3():S120-8. PubMed ID: 11779082 [TBL] [Abstract][Full Text] [Related]
34. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. Gasparini G; Longo R; Fanelli M; Teicher BA J Clin Oncol; 2005 Feb; 23(6):1295-311. PubMed ID: 15718328 [TBL] [Abstract][Full Text] [Related]
35. Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. McKeage MJ; Baguley BC Cancer; 2010 Apr; 116(8):1859-71. PubMed ID: 20166210 [TBL] [Abstract][Full Text] [Related]
36. Dose effects of continuous vinblastine chemotherapy on mammalian angiogenesis mediated by VEGF-A. Albertsson P; Lennernäs B; Norrby K Acta Oncol; 2008; 47(2):293-300. PubMed ID: 18210302 [TBL] [Abstract][Full Text] [Related]
37. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Wachsberger P; Burd R; Dicker AP Clin Cancer Res; 2003 Jun; 9(6):1957-71. PubMed ID: 12796357 [TBL] [Abstract][Full Text] [Related]
38. [A new treatment protocol targeting tumor vasculature--- metronomic chemotherapy combined radiotherapy]. Qiu H; Wang GM Ai Zheng; 2007 Dec; 26(12):1392-6. PubMed ID: 18076810 [TBL] [Abstract][Full Text] [Related]
39. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Kesari S; Schiff D; Doherty L; Gigas DC; Batchelor TT; Muzikansky A; O'Neill A; Drappatz J; Chen-Plotkin AS; Ramakrishna N; Weiss SE; Levy B; Bradshaw J; Kracher J; Laforme A; Black PM; Folkman J; Kieran M; Wen PY Neuro Oncol; 2007 Jul; 9(3):354-63. PubMed ID: 17452651 [TBL] [Abstract][Full Text] [Related]
40. Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance. Cao Y; Zhong W; Sun Y Semin Cancer Biol; 2009 Oct; 19(5):338-43. PubMed ID: 19481151 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]